🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Caplin Point Laboratories Limited CAPLIPOINT NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.caplinpoint.net
Company Profile ↓
₹2,221.60
+6.32% 1Y
Mkt Cap₹16,886.76 Cr
P/E25.45
P/B5.33
Div. Yield0.30%
52W High₹2,867.40
52W Low₹1,499.51
Book Value₹462.02
EPS (TTM)₹87.28

Company Overview

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 22.0%.

Consistent Profit Growth

Net profit has compounded at 19.4% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 25.4, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 29.1%.

Recent Developments

  • Mar 2026 Revenue of ₹2,187.19 Cr (+12.9% YoY); net profit ₹641.24 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.6%, earnings +15.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.6%, profit CAGR 19.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.58%
1 Year:19.60%

Compounded Profit Growth

5 Years:19.45%
1 Year:15.90%

Stock Price Performance

1 Year:+6.32%
6 Months:+29.66%
3 Months:-10.52%
1 Month:-19.41%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 53% of range
₹1,499.51 ₹2,867.40
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)24.95 · Oversold
Price Performance
1M-19.41%
3M-10.52%
6M+29.66%
1Y+6.32%
Valuation vs Sector

P/E of 25.45 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 22.0%.
  • Excellent profit margin of 29.1%.
  • Compounding revenue at 14.6% over 5 years.
  • Profit CAGR of 19.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • RSI at 25 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
25.45
Industry PE
36.43
Forward P/E
20.07
PEG Ratio
-
Book Value
₹462.02
Price to Book
5.33
P/S
8.18
EV/EBITDA
23.29
Dividend Yield
0.30%

Growth (CAGR)

Revenue 5Y
14.58%
Profit 5Y
19.45%
Revenue (YoY)
19.60%
Earnings (YoY)
15.90%

Profitability & Returns

ROCE
21.96%
ROE
17.88%
ROA
15.85%
Profit Margin
29.09%
Op Margin
31.43%
Gross Margin
59.97%
EPS (Latest Qtr)
₹22.31
EPS (TTM)
₹87.28

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
5.59
Current Ratio
6.70
Debt
₹4.61 Cr
Total Assets
₹4,045.48 Cr
Current Assets
₹2,585.66 Cr
Working Capital
₹2,199.72 Cr

Ownership

Promoter Holding
73.44%
Chg in Prom Hold
-0.17%
FII / Inst Holding
5.71%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹16,886.76 Cr
Total Revenue (TTM)
₹2,287.33 Cr
EBITDA
₹794.02 Cr
Free Cash Flow
₹275.10 Cr
Operating Cash Flow
₹523.23 Cr
Shares Outstanding
₹7.60 Cr
Gross Margin
59.97%
Payout Ratio
8.02%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CAPLIPOINT Caplin Point Laboratories Limited NIFTY_SMALLNSEPHARMA 2,221.60 25.45 ₹16,886.76 Cr 0.30% 21.96% 17.88% 14.58% 19.45%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 389.00 Cr395.00 Cr410.00 Cr436.00 Cr453.00 Cr459.00 Cr-492.96 Cr502.45 Cr510.22 Cr534.00 Cr542.77 Cr600.16 Cr
Cost of Revenue -------195.35 Cr201.20 Cr195.24 Cr-215.14 Cr245.00 Cr
Gross Profit -------297.61 Cr301.25 Cr314.98 Cr-327.63 Cr355.16 Cr
Operating Expenses 265.00 Cr269.00 Cr273.00 Cr293.00 Cr308.00 Cr307.00 Cr-151.52 Cr150.23 Cr153.51 Cr345.00 Cr157.22 Cr169.72 Cr
Operating Income 113.00 Cr116.00 Cr125.00 Cr128.00 Cr129.00 Cr136.00 Cr-146.09 Cr151.02 Cr161.47 Cr171.00 Cr170.41 Cr185.44 Cr
EBITDA 124.00 Cr127.00 Cr137.00 Cr142.00 Cr145.00 Cr152.00 Cr-193.64 Cr193.88 Cr200.93 Cr189.00 Cr223.35 Cr232.60 Cr
Interest Expense 000000-18.00 L17.00 L18.00 L018.00 L36.00 L
Pretax Income 124.00 Cr127.00 Cr146.00 Cr145.00 Cr146.00 Cr154.00 Cr-177.26 Cr176.67 Cr184.46 Cr201.00 Cr203.89 Cr213.44 Cr
Tax Provision 22.32 Cr22.86 Cr29.20 Cr26.10 Cr24.82 Cr29.26 Cr-37.19 Cr31.39 Cr33.70 Cr40.20 Cr38.03 Cr40.56 Cr
Net Income 101.00 Cr104.00 Cr116.00 Cr120.00 Cr121.00 Cr125.00 Cr-138.96 Cr142.57 Cr152.80 Cr160.00 Cr163.88 Cr170.11 Cr
Diluted EPS 13.4513.6215.1315.4316.0116.31-18.1918.6920.0320.3221.5122.31

Profit & Loss (Annual)

Figures in INR.

Metric Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 252.00 Cr239.00 Cr402.00 Cr540.00 Cr649.00 Cr863.00 Cr1,061.00 Cr-1,453.82 Cr1,679.55 Cr1,937.47 Cr2,187.19 Cr
Cost of Revenue --------669.27 Cr729.34 Cr770.84 Cr865.68 Cr
Gross Profit --------784.55 Cr950.21 Cr1,166.63 Cr1,321.51 Cr
Operating Expenses 192.00 Cr175.00 Cr276.00 Cr345.00 Cr417.00 Cr603.00 Cr732.00 Cr-386.19 Cr449.28 Cr585.66 Cr633.43 Cr
Operating Income 52.00 Cr57.00 Cr112.00 Cr176.00 Cr209.00 Cr228.00 Cr292.00 Cr-398.36 Cr498.00 Cr580.97 Cr688.08 Cr
EBITDA 60.00 Cr64.00 Cr125.00 Cr195.00 Cr232.00 Cr260.00 Cr329.00 Cr-497.12 Cr618.65 Cr743.35 Cr876.43 Cr
Interest Expense 1.00 Cr01.00 Cr1.00 Cr1.00 Cr02.00 Cr-78.00 L78.00 L61.00 L87.00 L
Pretax Income 53.00 Cr60.00 Cr121.00 Cr188.00 Cr227.00 Cr269.00 Cr314.00 Cr-451.35 Cr564.43 Cr676.78 Cr802.79 Cr
Tax Provision 12.19 Cr14.40 Cr25.41 Cr43.24 Cr49.94 Cr53.80 Cr62.80 Cr-74.36 Cr103.01 Cr135.69 Cr153.06 Cr
Net Income 41.00 Cr46.00 Cr96.00 Cr145.00 Cr177.00 Cr215.00 Cr251.00 Cr-376.26 Cr457.08 Cr536.31 Cr641.24 Cr
Diluted EPS 5.436.0512.6519.1523.3528.4232.03-49.1859.9070.2584.11

Balance Sheet (Annual)

Figures in INR.

Metric Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 229.00 Cr267.00 Cr358.00 Cr500.00 Cr743.00 Cr1,126.00 Cr1,364.00 Cr-2,191.40 Cr2,698.12 Cr3,207.85 Cr4,045.48 Cr
Current Assets --------1,552.19 Cr1,892.92 Cr2,133.95 Cr2,585.66 Cr
Cash & Equivalents --------484.47 Cr545.77 Cr583.20 Cr94.18 Cr
Inventory --------288.22 Cr363.04 Cr336.10 Cr428.86 Cr
Receivables --------394.06 Cr542.72 Cr632.49 Cr825.81 Cr
Total Liabilities --------284.13 Cr351.29 Cr321.46 Cr414.68 Cr
Current Liabilities --------268.00 Cr330.85 Cr305.99 Cr385.94 Cr
Long Term Debt ------------
Total Debt 2.00 Cr2.00 Cr1.00 Cr1.00 Cr36.00 Cr113.00 Cr235.00 Cr-5.48 Cr1.97 Cr5.02 Cr4.61 Cr
Total Equity 93.00 Cr128.00 Cr225.00 Cr364.00 Cr597.00 Cr873.00 Cr969.00 Cr-1,880.48 Cr2,315.71 Cr2,850.49 Cr3,586.42 Cr
Shares Outstanding --------7.59 Cr7.59 Cr7.60 Cr7.60 Cr

Cash Flows (Annual)

Figures in INR.

Metric Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 50.00 Cr42.00 Cr68.00 Cr66.00 Cr83.00 Cr45.00 Cr269.00 Cr-271.37 Cr318.39 Cr432.37 Cr523.23 Cr
Investing Cash Flow -23.00 Cr-6.00 Cr-36.00 Cr-69.00 Cr-100.00 Cr-54.00 Cr-30.00 Cr--217.58 Cr-320.04 Cr-334.73 Cr-582.29 Cr
Financing Cash Flow -9.00 Cr-14.00 Cr-7.00 Cr-12.00 Cr90.00 Cr80.00 Cr-24.00 Cr--28.17 Cr-38.07 Cr-38.32 Cr-46.46 Cr
Capital Expenditure -26.00 Cr-8.00 Cr-25.00 Cr-48.00 Cr-65.00 Cr-77.00 Cr-74.00 Cr--193.47 Cr-145.82 Cr-191.52 Cr-248.13 Cr
Free Cash Flow 24.00 Cr34.00 Cr43.00 Cr18.00 Cr18.00 Cr-32.00 Cr195.00 Cr-77.90 Cr172.57 Cr240.85 Cr275.10 Cr
Net Change in Cash 19.00 Cr23.00 Cr25.00 Cr-14.00 Cr73.00 Cr70.00 Cr215.00 Cr-25.62 Cr-39.72 Cr59.32 Cr-105.52 Cr

Ratios (Annual)

Figures in %.

Metric Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------54.0%56.6%60.2%60.4%
Operating Margin % 20.6%23.8%27.9%32.6%32.2%26.4%27.5%-27.4%29.7%30.0%31.5%
Net Margin % 16.3%19.2%23.9%26.9%27.3%24.9%23.7%-25.9%27.2%27.7%29.3%
ROE % 44.1%35.9%42.7%39.8%29.6%24.6%25.9%-20.0%19.7%18.8%17.9%
ROCE % --------20.7%21.0%20.0%18.8%

Shareholding Pattern

Insiders
73.44%
Institutions
5.71%
Public Float
21.50%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CAPLIPOINT

Google News hu, 25 Jun 2026

CAPLIPOINT Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1VY0VjRFBYXzZCWGtrbWNRNXhfdzNqSktNT09GLWFiLV9ha1EyLTJpamx2bFRjM245S0JuN1I2RkNYNmtpa1VQTmsyVUxjbHFDS09nTVVZMTNnTGRaaVA0QlVhclN6SFF5ZVFqd1ZwVFR5S1l0Z19XSjFaSjFHdw?oc=5" target="_blan…

Google News Sun, 24 May 2026

Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Looks Like A Good Stock, And It's Going Ex-Dividend Soon - Webull

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE91ZW9YOElnU1VwaGhFRWFiMWxhMjZKT3poVzFiVTk1N21qZ0lJTGlhV0FWaXJFWmtaajFBLXQ3ZFFjSFItTFY4S1M3QWtXeU9GR3R0LVZtekQ?oc=5" target="_blank">Caplin Point Laboratories Limited (NSE:CAPLIPOIN…

Google News Mon, 07 Sep 2026

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxPT2VQNXFobG1hcGdHTW1wVHRfYXEzdEpfN2RQTUVUQTBxY2Fza2hJempjTzFyeWEzTG43YnFTWWRSM0pRcE44cm1wYnRJSUdmZkI5c2JXQnk1TWVzWm8zbFBlTFNRUWlQQmZQZmJUeGVraUJQVGd5SGQwdVlyZ3Nfay1sVjN4Rzg5MnNBdk…

Google News Fri, 09 Oct 2026

Caplin Point Laboratories Share Price Fall and Valuation - Univest

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNc1Q3eFpBTEJiS2dBcGlWYjJ3Mjg1dVN4dmV2V3pGWWxELU90TVlEeEFielBtdEhOMG9mbEcyZ0JNaWxtMlhBQnhWaTdFcnFnVEQxR2lmZkZLQ3NzYTNUWWktcW1qZUFyUjVaUUtydFRabEdSTERIVm4zakJHbmNmcGd6LXlhUDBBWkltd0…

Google News Fri, 02 Oct 2026

CAPLIPOINT Q2 2026 Earnings: Double-Digit Revenue Growth Offset by Soft Stock Reaction - Pre-Announcement Alert - siam.in

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNSmtIZ1I1bGhiRFhMWTA5Um1rZHZYLUJSOEx2ZEtpSlRKUzRpN0NWMUtwQWM4VFRPa2pMSDZYU2xwZ0pubm1RVU1BUk5wRnVsOUR6ZktNTmI3SmV0WEFxei1Ub19ESFo5aTVuVmZKMHlhYmVDcGhpUUJ6TlhEX29QNTdXVzNuYUx2UlMxaH…

Google News ue, 08 Sep 2026

Caplin Point Lab stock delivers decisive breakout; Axis Direct shares buy range, stop loss, upside and holding period - TradingView

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxOSnFuUlljNG5lc2lENEpfVXFJdkUtU3UwdGJYSFJuNjRGNFVQa3VSLVp0UUFpRGRZTnhfQzEyZzdPM3hfQmE0Rk4wczhYd2J4QXpjY2pCeHdGcDRxcDJiTlVxamlYamVtYjFEMVNQcmItdG9Id00tZDNTSFI0VHBZdWU3TmpCd3JZNVdNQn…

CAPLIPOINT — Frequently Asked Questions

What is the current share price of Caplin Point Laboratories Limited (CAPLIPOINT)?

As of 2026-10-23 04:58 IST, Caplin Point Laboratories Limited (CAPLIPOINT) trades at ₹2,221.60 on NSE. Its 52-week range is ₹1,499.51 to ₹2,867.40.

What is the market capitalisation of CAPLIPOINT?

Caplin Point Laboratories Limited (CAPLIPOINT) has a market capitalisation of ₹16,886.76 Cr on NSE.

What is the P/E ratio of CAPLIPOINT?

CAPLIPOINT trades at a trailing price-to-earnings (P/E) ratio of 25.45. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 5.33.

Does CAPLIPOINT pay a dividend?

Caplin Point Laboratories Limited (CAPLIPOINT) currently offers a dividend yield of 0.30%.

What is the return on equity (ROE) of CAPLIPOINT?

CAPLIPOINT has a return on equity (ROE) of 17.88%. Its return on capital employed (ROCE) is 21.96%.

Is CAPLIPOINT a good stock to buy?

This page provides a data-driven analysis of Caplin Point Laboratories Limited (CAPLIPOINT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space